Lead Sponsor

Bristol-Myers Squibb

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Diagnosis of B-CLL by NCI criteria
•Require chemotherapy and have fully recovered from previous administered chemotherapy
•Subjects must have progressed, failed to achieve a meaningful response, or relapsed/intolerant to prior therapy. Failing at least one purine analogue regimen
•Subjects have received three or fewer prior treatment regimens
•ECOG status of 0 - 2
•If dose level + 3 is reached, the criteria is the same as outlined for Cohort #1, however the subjects should not have a history of prior chemotherapy (treatment naive)

•Unwilling or unable to use an acceptable method to avoid pregnancy
•Uncontrolled or significant cardiovascular disease, including prolonged QTc interval
•History of significant bleeding disorder, unrelated to CLL
•Prior concurrent malignancy
•Drugs that generally accepted to have the risk of causing Torsades de Pointes
•Autoimmune hemolytic anemia requiring therapy or transfusion support
•Autoimmune thrombocytopenia requiring steroid therapy or transfusion support
•Richter's Syndrome
•Transformation to prolymphocytic leukemia

Related studies

NCT06846671 · CLL, Chronic Lymphocytic Leukemia

NCT07218341 · Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic

NCT06548152 · Chronic Lymphocytic Leukemia

NCT07030400 · Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL)

NCT07277231 · Chronic Lymphocytic Leukemia

Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia